The Latest Cardiac and Vascular News
ReadyFix will first be deployed with GE HealthCare’s MAC VU360* resting electrocardiogram (ECG) workstations to help optimize cardiac care delivery by reducing device disruptions. Through real-time** data and remote device diagnostic capabilities, ReadyFix can help healthcare systems proactively maintain and optimize MAC VU360 devices anywhere in the hospital — supporting […]
WESTMINSTER, Colo.–(BUSINESS WIRE)–TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced changes to its Board of Directors. TriSalus announced that Dr. Arjun “JJ” Desai, a member […]
MIAMI, Feb. 9, 2026 /PRNewswire/ — Researchers and surgeons at Florida International University (FIU) are helping turn the tide on cardiovascular disease, the leading cause of death in the United States, through early detection, advanced surgery and collaborative innovation. Experience…
SAN DIEGO, Feb. 9, 2026 /PRNewswire/ — Atraverse Medical today announced the presentation of new clinical and preclinical data at AF Symposium 2026 in Boston, further validating the safety, performance, and workflow advantages of the company’s HOTWIRE™ Transseptal Access System. Findings…
FAYETTEVILLE, Ark., Feb. 9, 2026 /PRNewswire/ — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused healthcare accelerator that facilitates guaranteed hospital pilot projects and clinical trials for accomplished, early-stage companies bringing…
ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany.
DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the recently adopted FY 2026 U.S. Department of Defense (DoD) Appropriations Act includes dedicated funding to support the evaluation and incorporation of biologic vascular repair technologies for the warfighters suffering from traumatic vascular injuries.
HONG KONG, Feb. 9, 2026 /PRNewswire/ — Peijia Medical Limited (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developed GeminiOne Transcatheter Edge-to-Edge Repair (TEER)…
Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical data from the nPulse Cardiac […]
The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence LATHAM, N.Y.–Feb. 5, 2026– AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, and […]
